Free, Online & With Nursing Content!
8 Hour Training + 16 Hour Training = 24 Hours of Education Required to Obtain a DEA MAT Waiver for More Than 30 Patients
Register now for these 2 FREE courses on medications for addictions treatment (MAT) and:
- Complete 24 hours of education required to obtain a DEA waiver to prescribe MAT (including buprenorphine) for opioid use disorders for more than 30 patients.
- Earn 24 NCPD contact hours in pharmacology
- Get a solid foundation in practices to decrease opioid use and opioid related deaths.
- Explore issues you might encounter when assessing and providing MAT to persons with opioid use disorders.
- Understand how current regulations affect your role and responsibilities as a provider.
Note that these are two standalone courses which will each come with a CE certificate. Instructions for obtaining a DEA waiver will be sent upon completion of the 24 hours of training.
In accordance with 2021 changes in practice guidelines for administering buprenorphine for the treatment of opioid use disorder, Advanced Practice Registered Nurses (APRN) are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine. To treat more than 30 patients, providers must complete 24 hours of specialized training to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder.
Effective Treatments for Opioid Use Disorders
Free nursing continuing professional development: This continuing educational activity was developed by the American Psychiatric Nurses Association to provide education to all nurses regarding the epidemic of opioid use in the U.S. and to answer the question, What can nurses do?” to address this growing problem. Almost 4 million nurses can make a difference!
Opioid Response Network – Lessons Learned, Promising Models, Education
A coalition of the American Academy of Addiction Psychiatry (AAAP) and 27 national professional organizations, including APNA. This two-year SAMHSA grant helps to provide technical assistance (TA) to states and territories to enhance efforts already underway throughout the United States and territories. ORN provides training and technical assistance via local experts across the country, focusing on applying evidence-based practices in prevention, treatment and recovery to meet locally identified needs.
Providers Clinical Support System – Education, Mentoring, Clinical Resources
A national training and clinical mentoring project developed in response to the opioid use disorder crisis. With resources and training developed for primary care providers, the overarching goal of PCSS is to provide the most effective evidenced-based clinical practices in the prevention of OUD through proper opioid prescribing practices, identifying patients with OUD, and the treatment of opioid use disorder.
(November 8, 2019) Update from Medicaid and CHIP Payment and Access Commission (MACPAC) meeting:
At its October 31, 2019, meeting, the Medicaid and CHIP Payment and Access Commission (MACPAC) presented its findings on the impact of authorizing NPs and PAs to obtain a waiver to prescribe medication-assisted treatment (MAT) in the Comprehensive Addiction and Recovery Act (CARA). The presentation highlighted that this authorization in CARA increased access to treatment for patients in need of MAT. This increase in access was most pronounced in the Medicaid population, and nurse practitioners (NPs) and physician assistants (PAs) made up a higher proportion of rural waived providers. The presentation also noted that the increase in access was greatest in full practice authority states. This data shows that authorizing NPs to prescribe MATs is crucial to combat the opioid epidemic, but state barriers to practice lead to inequality in access to this important treatment. Access the slides presented by MACPAC.
(August 24, 2017) Clarification received from SAMHSA:
Nurse practitioners and physician assistants may use their waiver to prescribe buprenorphine products for the treatment of opioid use disorder in any healthcare setting including OTPs. However, the healthcare setting or employer, OTP or otherwise, is free to establish by policy which services are to be provided and by which professionals. Any practitioner who uses the waiver to treat patients must comply with their patient limit regardless of the treatment setting. Nurse practitioners and physician assistants may order buprenorphine or methadone for administration or dispensing from an OTP without a DATA waiver, but must receive an exemption from SAMHSA to make dose and administration adjustments.
(May 19, 2017) Here are updates to the three aspects of the MAT waiver process for APRNs: the required 24 hours of education, the process for issuing MAT waivers, and the regulations for implementing the CARA 2016 legislation.
- Educational Content for Required Training
PCSS-MAT waiver training coursework has been released. Access the course here free of charge.
- OMB Approval of MAT Waiver Issuance Process
From SAMHSA Website as of February 28, 2017:
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI. NPs and PAs may send copies of their training certificates to firstname.lastname@example.org or faxed them to 301-576-5237.
These waiver applications will be forwarded to the DEA, which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number. SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
- HHS Regulation to Implement CARA 2016
No further HHS regulation is needed before eligible NPs or PAs with a properly authorized wavier can begin prescribing buprenorphine, subject to applicable statutory patient limits.